Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with.

Slides:

Advertisements

Similar presentations

SABA (short acting beta agonist) inhalers Aerosol InhalersGeneric Component No of doses Cost/ device Dosing directions Ventolin evohalerSalbutamol 100mcg/dose200£

Advertisements

New inhalers for COPD and asthma 2015

Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.

Practical Recommendations for COPD:

Vitamin D3 increased ASL antimicrobial activity.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.

Study sample selection process.

Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.

Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.

Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,

Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.

Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.

Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)

(A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England,

DSM-IV delirium prevalence, including the estimated delirium prevalence in the 31 patients that did not undergo delirium assessment following initial screening.

Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.

A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.

A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.

NMA results for HA RRMS. ARR, annualised relapse rate; BID, two times a day; CrI, credible interval; DMF, dimethyl fumarate; HA, highly active; NMA, network.

1-year and 5-year survival rates by cancer type, stage and group, England, up to 2011– year and 5-year survival rates by cancer type, stage and.

Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.

Keratinocyte growth factor (KGF) versus no KGF for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic.

Time trend projections of age-standardised death rate (ASDR) per 100 000 individuals. Time trend projections of age-standardised death rate (ASDR) per.

Governance and information centre requirements prior to application approval. s251, section 251 of the NHS 2006 Act; ONS, Office for National Statistics;

Numbers of excess or lower than expected deaths for each place of death. Numbers of excess or lower than expected deaths for each place of death. Separate.

Dose–response curve for the rate ratio (solid line) and 95% CIs (dashed lines) of pneumonia as a function of inhaled corticosteroid dose in μg (measured.

Distribution of total possible savings (y-axis), showing how much total saving there would be if only those over £x per practice per month (x-axis) were.

Proportions of discharge diagnoses or death following first readmission/death within 30 or 180 days after initial discharge, according to the presence.

Results of comparisons of treatments in the network.

Knowledge gaps in key risk factor numbers

Affected and unaffected prefectures in northeast Japan

Summary of search results: (A) Research applications receiving a final favourable opinion between 1 January and 30 June 2016, falling into the first four.

Practical Recommendations for COPD:

Subject disposition through week 156 of treatment

COPD Action Plan adherence.

Contour enhanced funnel plot for the random effects meta-analysis of the mean difference in total daily energy intake (kcal/day), based on breakfast consumption.

Difference in cumulative revision of knee constructs compared with a contemporary benchmark at 7 years in men aged between 55 years and 75 years, using.

Targeted Care for COPD.

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Cryotherapy versus no cryotherapy for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic stem.

Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to minimum observed white blood cell.

Factors associated with preparedness competency of public health inspectors from the qualitative analysis, which are grouped into three levels according.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Time trends in the number of monthly admissions throughout the study period. Time trends in the number of monthly admissions throughout the study period.

Bubble plot with a fitted meta-regression line of the log prevalence of commercial pad use by adolescent girls over time, 104 studies in India published.

Prevalence of prescribing of different anti-diabetic medications among all patients with type 2 diabetes on treatment. *Other=Sum of prevalence of Acarbose,

Fig 4 Population level predicted proportions of cutaneous melanocytic biopsy interpretations that would be verified by the consensus reference panel or.

Absolute survival probability (per cent who have not quit successfully) of reported quit attempts of longer than 1 year during the first 18 months of observation.

Overview of the strength of evidence of non-pharmacological and pharmacological interventions compared with inactive interventions for the treatment of.

Showing (A) the reported activity of community midwifery teams in recommending and providing seasonal influenza vaccination to pregnant women and (B) the.

Eye position of positional nystagmus in the right-ear-down and left-ear-down head positions in patients with horizontal canal type of benign paroxysmal.

Fig 2 Predicted probabilities of being in each of the five change in substance use categories (change from baseline in average daily amount of main substance)

Study designs for double-blind single maintenance and reliever therapy (SMART) studies. Study designs for double-blind single maintenance and reliever.

Predicted survival curves for hip replacements for two male and two female hypothetical individuals with different levels of blood cobalt at 2 and 5 µg/l.

Themes of Positionality, Core Concepts, Social/Environmental Factors, and Paradigms/Theories/Models. *Indicates answers specifically from the third open-ended.

Distribution of product medicinal products without commercial interest (MPWCI) presentations (original list) studied due to the age of the marketing authorisation.

Determinants of moderate Cardiovascular Health Index Score (achieving three or more risk factor targets), stratified by region conventions as in figure.

Representativeness of linked cancer registry and dispensed prescription data as compared with cancer registry data alone, by key patient and tumour characteristics.

Health states and movement between health states in Markov model.

Kaplan-Meier survival curves by severity of exacerbations in patients with COPD: (1) no acute exacerbations of COPD; (2) patients with acute exacerbations.

The effect of vitamin C on postexercise forced expiratory volume in 1 s (FEV1) decline as a function of the placebo-day postexercise FEV1 decline for the.

Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.

Standardised patient wearing the obesity simulation suit used in the present study to represent a patient with type 2 diabetes and grade 2 obesity. The.

Number of hospital presentations for self-harm in Derby from 2003 to 2012 (inclusive) based on Multicentre Study data, Hospital Episode Statistics (HES)

Forest plot of the prevalence rates of acne according to region.

Kaplan–Meier plot of proportion of persons convicted (excluding traffic offenses) for the first time in the background population (thin line) and in men.

Presentation transcript:

Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with placebo. Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with placebo. The black horizontal lines represent the 95% CIs of the summary treatment effects BUDE, budesonide; FLUT, fluticasone; FORM, formoterol; INDAC, indacaterol; SALM, salmeterol; VILA, vilanterol; GLYC, glycopyrronium bromide; TIOT, tiotropium; FORM/BECLO, formoterol/beclomethasone; FORM/BUDE, formoterol/budesonide; VILA/FLUT, vilanterol/fluticasone; SALM/FLUT, salmeterol/fluticasone; TIOT/SALM, tiotropium/salmeterol; INDA/GLYC, indacaterol/glycopyrronium; TIOT/FLUT/SALM, tiotropium/fluticasone/salmeterol; TIOT/BUDE/FORM, tiotropium/budesonide/formoterol. Andrea C Tricco et al. BMJ Open 2015;5:e009183 ©2015 by British Medical Journal Publishing Group